婦人科がん治療薬の世界市場レポート 2025年

婦人科がん治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）6.7％で203億6,000万米ドルに成長します。予測期間の成長は、罹患率の増加、バイオマーカー研究の進歩、政府の資金援助と支援、高齢化人口の増加、臨床試験の進歩などに起因すると考えられます。予測期間の主な動向には、健康の公平性とアクセスへの取り組み、診断ツールの進歩、併用療法と標的薬剤、遠隔医療と遠隔モニタリング、患者中心のケアモデル、共同研究とパートナーシップなどがあります。

婦人科がんの流行は、今後の婦人科がん治療薬市場の成長を牽引するものと思われます。婦人科がんには、女性の生殖器官に由来するがんが含まれ、これらの症状に合わせた薬剤は、その有病率を低下させる上で重要な役割を果たしています。これらの薬剤は、婦人科がんの治療と管理、再発予防、多様な治療アプローチによる患者の転帰の改善に役立っています。例えば、2022年2月に世界卵巣がん連合が発表したデータによると、卵巣がんは2020年に世界で313,959人の女性に罹患し、この数は2040年までに42％増加して445,721人になると予測されています。同じ期間に、卵巣がんで死亡する女性の数は、207,252人から313,617人へと51％増加すると予想されています。したがって、婦人科がんの有病率の上昇は、婦人科がん治療薬市場拡大の主要な促進要因です。

婦人科がん治療薬市場の成長は、消費者の健康意識の高まりによって促進されると予測されます。健康意識には、健康、ヘルスケアサービス、健康ニーズに対する包括的な理解が含まれます。婦人科がんの場合、健康意識の向上は早期発見・早期治療に不可欠であり、治療成績の大幅な改善につながります。これは、病気、健康リスク、予防の重要性について個人を教育し、健康を管理できるようにする取り組みです。例えば、2023年8月にKoninklijke DSM N.V.が発表した報告書によると、パンデミック（世界的大流行）を受けて、世界の消費者の60％が健康に関心を持つようになり、健康上の問題を回避するために健康的な生活を送ることをより優先するようになった。したがって、消費者の健康意識の高まりは、婦人科がん治療薬市場拡大の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界婦人科がん治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の婦人科がん治療薬市場：成長率分析
• 世界の婦人科がん治療薬市場の実績：規模と成長, 2019-2024
• 世界の婦人科がん治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界婦人科がん治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の婦人科がん治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アルキル化剤
• 植物アルカロイド
• アントラサイクリン
• 抗腫瘍抗生物質
• その他のタイプ
• 世界の婦人科がん治療薬市場治療法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 標的療法
• ホルモン療法
• 世界の婦人科がん治療薬市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 子宮頸がん
• 子宮がん
• 卵巣がんおよび卵管がん
• 外陰がん
• 膣がん
• 世界の婦人科がん治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 専門がん治療センター
• その他のエンドユーザー
• 世界の婦人科がん治療薬市場アルキル化剤の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• シクロホスファミド
• イホスファミド
• カルムスチン
• 世界の婦人科がん治療薬市場植物アルカロイドの種類によるサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• パクリタキセル
• ドセタキセル
• ビンクリスチン
• 世界の婦人科がん治療薬市場アントラサイクリン系薬剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ドキソルビシン
• エピルビシン
• ダウノルビシン
• 世界の婦人科がん治療薬市場抗腫瘍抗生物質の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アクチノマイシンD
• マイトマイシンC
• 世界の婦人科がん治療薬市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ホルモン療法
• 標的療法
• 免疫療法

第7章 地域別・国別分析

• 世界の婦人科がん治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の婦人科がん治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 婦人科がん治療薬市場：競合情勢
• 婦人科がん治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Bristol-Myers Squibb
• Sanofi S.A.
• AstraZeneca
• GlaxoSmithKline
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Merck KGaA
• Baxter International Inc.
• Eisai Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries
• Ipsen
• Dr. Reddy's Laboratories

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 婦人科がん治療薬市場2029：新たな機会を提供する国
• 婦人科がん治療薬市場2029：新たな機会を提供するセグメント
• 婦人科がん治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Gynecological cancer drugs constitute pharmaceutical products specifically formulated for the treatment of cancers and malignancies affecting the female reproductive system. These drugs are designed to target cancer cells, either destroying them, inhibiting their growth, or preventing the spread of malignant cells.

The primary categories of gynecological cancer drugs include alkylating agents, plant alkaloids, anthracyclines, antitumor antibiotics, and others. Alkylating agents, for instance, are a type of chemotherapy drug that disrupts the DNA of cancer cells, impeding their replication and inducing cell death. In gynecological cancer treatment, these drugs serve as cytotoxic treatments to target and eliminate cancer cells in reproductive organs such as the ovaries, uterus, cervix, and more. Various therapeutic modalities, including chemotherapy, targeted therapy, and hormonal therapy, are employed for different indications such as cervical cancer, uterine cancer, ovarian and fallopian tube cancer, vulvar cancer, and vaginal cancer. These treatments are administered in diverse healthcare settings, including hospitals, clinics, specialized cancer treatment centers, and other medical facilities.

The gynecological cancer drugs market research report is one of a series of new reports from The Business Research Company that provides gynecological cancer drugs market statistics, including gynecological cancer drugs industry global market size, regional shares, competitors with a gynecological cancer drugs market share, detailed gynecological cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gynecological cancer drugs industry. This gynecological cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gynecological cancer drugs market size has grown strongly in recent years. It will grow from $14.69 billion in 2024 to $15.69 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to growing advancements in chemotherapy, hormone therapy developments, early detection and diagnosis, surgical innovations, government funding and research grants, increasing awareness and screening programs

The gynecological cancer drugs market size is expected to see strong growth in the next few years. It will grow to $20.36 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to increasing incidence rates, advancements in biomarker research, government funding and support, growing aging population, clinical trial advancements. Major trends in the forecast period include health equity and access initiatives, advancements in diagnostic tools, combination therapies and targeted agents, telemedicine and remote monitoring, patient-centric care models, collaborations and partnerships.

The prevalence of gynecological cancer is poised to drive the growth of the gynecological cancer drugs market in the future. Gynecologic cancer encompasses cancers originating in a woman's reproductive organs, and drugs tailored for these conditions play a crucial role in reducing their prevalence. These drugs are instrumental in treating and managing gynecological cancer, preventing recurrence, and enhancing patient outcomes through diverse therapeutic approaches. For example, data from the World Ovarian Cancer Coalition in February 2022 indicated that ovarian cancer affected 313,959 women globally in 2020, and this number is projected to increase by 42% to 445,721 by 2040. Over the same period, there is an expected 51% rise in the number of women succumbing to ovarian cancer, from 207,252 to 313,617. Hence, the elevated prevalence of gynecological cancer is a key driver for the expansion of the gynecological cancer drugs market.

The growth of the gynecological cancer drug market is anticipated to be propelled by the increasing health awareness among consumers. Health awareness involves a comprehensive understanding of health, healthcare services, and health needs. In the context of gynecological cancer, heightened health awareness is critical for early detection and treatment, significantly improving outcomes. It encompasses initiatives to educate individuals about diseases, health risks, and the importance of prevention, empowering them to take control of their health. For instance, a report from Koninklijke DSM N.V. in August 2023 highlighted that in response to the pandemic, 60% of consumers worldwide are now more concerned about their health, placing a higher priority on leading healthy lives to avoid health problems. Therefore, the growing health awareness among consumers acts as a driving force for the expansion of the gynecological cancer drug market.

Major companies in the gynecological cancer drugs market are developing alkylating agents to enhance treatment efficacy by targeting the DNA of cancer cells, thus preventing their proliferation. Alkylating agents function by adding alkyl groups to DNA, which can cause the strands to break or create abnormal cross-links, disrupting the cell cycle. For example, in June 2024, Shorla Oncology, an Ireland-based pharmaceutical company, announced that the FDA had approved Tepylute, an alkylating agent. Tepylute is available as a liquid formulation, eliminating the need for complex reconstitution processes typically associated with powder forms. It is indicated for patients with adenocarcinoma of the breast and ovary, conditions that can be particularly difficult to treat due to late-stage diagnosis and varied responses to existing therapies.

Key players in the gynecological cancer drug market are directing their focus toward personalized cancer vaccines to enhance customer offerings. Personalized cancer vaccines represent an emerging treatment approach that leverages a patient's own cancer cells to develop a vaccine aimed at instructing the immune system on how to recognize and eliminate the cancer. Pharmaceutical companies are integrating genetic sequencing and precision medicine to develop novel drug therapies and cancer treatments tailored to specific patients. For example, in January 2023, BioNTech, a Germany-based biotechnology company, announced plans to initiate trials for personalized cancer vaccines in the UK by September 2023. The company further aims to conduct tests and deliver 10,000 personalized mRNA therapies, including cancer vaccines, by the end of 2030.

In April 2023, SK Capital Partners LP, a US-based investment firm, acquired Apotex Pharmaceutical Holdings Inc. for an undisclosed amount. This acquisition allows SK Capital to enhance its portfolio by leveraging Apotex's expertise in developing gynecological cancer drugs. Apotex Pharmaceutical Holdings Inc. is a Canada-based company specializing in the creation of gynecological cancer medications.

Major companies operating in the gynecological cancer drugs market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb, Sanofi S.A., AstraZeneca, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Merck KGaA, Baxter International Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries, Ipsen, Dr. Reddy's Laboratories, Cipla Ltd., Apotex Inc., Hikma Pharmaceuticals, Seagen Inc., CSL Vifor, Accord Healthcare

North America was the dominant region in the gynecological cancer drugs market in 2024. The regions covered in the gynecological cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gynecological cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gynecological cancer drugs market consists of revenues earned by entities by providing immunotherapy, anti-angiogenesis, and radiation therapy. The market value includes the values of related goods sold by the service provider or included within the service offering. The gynecological cancer drugs market also includes sales of platinum-based chemotherapy drugs, taxane-based chemotherapy drugs, PARP inhibitors, and angiogenesis inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gynecological Cancer Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gynecological cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gynecological cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gynecological cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Alkylating Agent; Plant Alkaloid; Anthracyclines; Antitumor Antibiotic; Other Types
• 2) By Therapeutic Modality: Chemotherapy; Targeted Therapy; Hormonal Therapy
• 3) By Indication: Cervical Cancer; Uterine Cancer; Ovarian And Fallopian Tube Cancer; Vulvar Cancer; Vaginal Cancer
• 4) By End Users: Hospitals; Clinics; Specialized Cancer Treatment Centers; Other End Users
• Subsegments:
• 1) By Alkylating Agent: Cyclophosphamide; Ifosfamide; Carmustine
• 2) By Plant Alkaloid: Paclitaxel; Docetaxel; Vincristine
• 3) By Anthracyclines: Doxorubicin; Epirubicin; Daunorubicin
• 4) By Antitumor Antibiotic: Actinomycin D; Mitomycin C
• 5) By Other Types: Hormonal Therapies; Targeted Therapies; Immunotherapies
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gynecological Cancer Drugs Market Characteristics

3. Gynecological Cancer Drugs Market Trends And Strategies

4. Gynecological Cancer Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Gynecological Cancer Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Gynecological Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Gynecological Cancer Drugs Market Growth Rate Analysis
• 5.4. Global Gynecological Cancer Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Gynecological Cancer Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Gynecological Cancer Drugs Total Addressable Market (TAM)

6. Gynecological Cancer Drugs Market Segmentation

• 6.1. Global Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alkylating Agent
• Plant Alkaloid
• Anthracyclines
• Antitumor Antibiotic
• Other Types
• 6.2. Global Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Targeted Therapy
• Hormonal Therapy
• 6.3. Global Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cervical Cancer
• Uterine Cancer
• Ovarian and Fallopian Tube Cancer
• Vulvar Cancer
• Vaginal Cancer
• 6.4. Global Gynecological Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Specialized Cancer Treatment Centers
• Other End Users
• 6.5. Global Gynecological Cancer Drugs Market, Sub-Segmentation Of Alkylating Agent, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cyclophosphamide
• Ifosfamide
• Carmustine
• 6.6. Global Gynecological Cancer Drugs Market, Sub-Segmentation Of Plant Alkaloid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Paclitaxel
• Docetaxel
• Vincristine
• 6.7. Global Gynecological Cancer Drugs Market, Sub-Segmentation Of Anthracyclines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Doxorubicin
• Epirubicin
• Daunorubicin
• 6.8. Global Gynecological Cancer Drugs Market, Sub-Segmentation Of Antitumor Antibiotic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Actinomycin D
• Mitomycin C
• 6.9. Global Gynecological Cancer Drugs Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormonal Therapies
• Targeted Therapies
• Immunotherapies

7. Gynecological Cancer Drugs Market Regional And Country Analysis

• 7.1. Global Gynecological Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Gynecological Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gynecological Cancer Drugs Market

• 8.1. Asia-Pacific Gynecological Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gynecological Cancer Drugs Market

• 9.1. China Gynecological Cancer Drugs Market Overview
• 9.2. China Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gynecological Cancer Drugs Market

• 10.1. India Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gynecological Cancer Drugs Market

• 11.1. Japan Gynecological Cancer Drugs Market Overview
• 11.2. Japan Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gynecological Cancer Drugs Market

• 12.1. Australia Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gynecological Cancer Drugs Market

• 13.1. Indonesia Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gynecological Cancer Drugs Market

• 14.1. South Korea Gynecological Cancer Drugs Market Overview
• 14.2. South Korea Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gynecological Cancer Drugs Market

• 15.1. Western Europe Gynecological Cancer Drugs Market Overview
• 15.2. Western Europe Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gynecological Cancer Drugs Market

• 16.1. UK Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gynecological Cancer Drugs Market

• 17.1. Germany Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gynecological Cancer Drugs Market

• 18.1. France Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gynecological Cancer Drugs Market

• 19.1. Italy Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gynecological Cancer Drugs Market

• 20.1. Spain Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gynecological Cancer Drugs Market

• 21.1. Eastern Europe Gynecological Cancer Drugs Market Overview
• 21.2. Eastern Europe Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gynecological Cancer Drugs Market

• 22.1. Russia Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gynecological Cancer Drugs Market

• 23.1. North America Gynecological Cancer Drugs Market Overview
• 23.2. North America Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gynecological Cancer Drugs Market

• 24.1. USA Gynecological Cancer Drugs Market Overview
• 24.2. USA Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gynecological Cancer Drugs Market

• 25.1. Canada Gynecological Cancer Drugs Market Overview
• 25.2. Canada Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gynecological Cancer Drugs Market

• 26.1. South America Gynecological Cancer Drugs Market Overview
• 26.2. South America Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gynecological Cancer Drugs Market

• 27.1. Brazil Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gynecological Cancer Drugs Market

• 28.1. Middle East Gynecological Cancer Drugs Market Overview
• 28.2. Middle East Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gynecological Cancer Drugs Market

• 29.1. Africa Gynecological Cancer Drugs Market Overview
• 29.2. Africa Gynecological Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Gynecological Cancer Drugs Market, Segmentation By Therapeutic Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Gynecological Cancer Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gynecological Cancer Drugs Market Competitive Landscape And Company Profiles

• 30.1. Gynecological Cancer Drugs Market Competitive Landscape
• 30.2. Gynecological Cancer Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Gynecological Cancer Drugs Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Bristol-Myers Squibb
• 31.3. Sanofi S.A.
• 31.4. AstraZeneca
• 31.5. GlaxoSmithKline
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Amgen Inc.
• 31.9. Merck KGaA
• 31.10. Baxter International Inc.
• 31.11. Eisai Co. Ltd.
• 31.12. Sun Pharmaceutical Industries Ltd.
• 31.13. Teva Pharmaceutical Industries
• 31.14. Ipsen
• 31.15. Dr. Reddy's Laboratories

32. Global Gynecological Cancer Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gynecological Cancer Drugs Market

34. Recent Developments In The Gynecological Cancer Drugs Market

35. Gynecological Cancer Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Gynecological Cancer Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Gynecological Cancer Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Gynecological Cancer Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer